《2024年乳腺癌最新进展第二部分 - 早期乳腺癌患者》 - Suppr

Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.

作者信息

Janni Wolfgang, Kolberg Hans-Christian, Hartkopf Andreas D, Fehm Tanja N, Welslau Manfred, Müller Volkmar, Schütz Florian, Fasching Peter A, Jackisch Christian, Marme Frederik, Hörner Manuel, Keller Katharina, Goossens Chloë, Belleville Erik, Untch Michael, Thill Marc, Tesch Hans, Ditsch Nina, Lux Michael P, Banys-Paluchowski Maggie, Wöckel Achim, Harbeck Nadia, Stickeler Elmar, Bartsch Rupert, Aktas Bahriye, Schneeweiss Andreas, Ettl Johannes, Taran Florin-Andrei, Lüftner Diana, Würstlein Rachel, Radosa Julia C

机构信息

Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.

Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.

出版信息

Geburtshilfe Frauenheilkd. 2025 May 15;85(5):493-506. doi: 10.1055/a-2533-2783. eCollection 2025 May.

This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.